Format

Send to

Choose Destination
Cancer Treat Rev. 2018 Jul;68:102-110. doi: 10.1016/j.ctrv.2018.06.005. Epub 2018 Jun 11.

Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

Author information

1
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
2
Clinical Medicine and Surgery Department, University of Naples Federico II, 80131 Naples, Italy.
3
Department of Medical Oncology, Bellaria Hospital, Azienda USL Bologna, 40139 Bologna, Italy.
4
Oncology Unit, Giovanni Paolo II Hospital, 07026 Olbia, Italy.
5
Center of Experimental Oncology and Haematology, University of Catania, 95131 Catania, Italy.
6
Department of Medical Oncology, IRCCS Azienda Ospedaliera Universitaria San Martino-IST, Genoa, Italy.
7
Breast Unit, 'Fondazione G. Pascale' Istituto Nazionale Tumori, 80131 Naples, Italy.
8
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy; Department of Clinical Oncology, CRO Aviano National Cancer Institute, 33081 Aviano, Italy.
9
Clinical Medicine and Surgery Department, University of Naples Federico II, 80131 Naples, Italy. Electronic address: grazia.arpino@unina.it.

Abstract

Triple negative breast cancer (TNBC) represents the 15-20% of all breast cancers (BC) and is characterized by a very aggressive behavior. Recent data suggest that TNBC is not a single disease, but it is rather an umbrella for different ontology-profiles such as basal like 1 and 2, mesenchymal, and the luminal androgen receptor (LAR). The LAR subtype is characterized by the expression of the Androgen Receptor (AR) and its downstream effects. Notwithstanding the role of the AR in several signaling pathways, its impact on a biological and clinical standpoint is still controversial. The LAR subtype has been associated with better prognosis, less chemotherapy responsiveness and lower pathologic complete response after neoadjuvant treatment. Clinical evidence suggests a role for anti-androgen therapies such as bicalutamide, enzalutamide and abiraterone, offering an interesting chemo-free alternative for chemo-unresponsive patients, and therefore potentially shifting current treatment strategies.

KEYWORDS:

Antiandrogen therapy; Epithelial-to-Mesenchymal Transition; Luminal androgen receptor positive; Triple negative breast cancer

PMID:
29940524
DOI:
10.1016/j.ctrv.2018.06.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center